Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing eye care therapeutics. Its flagship product, XDEMVY, treats Demodex blepharitis by eradicating eyelid mites. The company also develops treatments for ocular rosacea, Lyme disease prophylaxis, and other infectious diseases, leveraging its proprietary lotilaner-based pipeline. Its core value lies in addressing unmet medical needs with innovative, parasite-targeting therapies for global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.